Cargando…

Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators

BACKGROUND: The construction of a nanoimmune controlled-release system that spatiotemporally recognizes tumor lesions and stimulates the immune system response step by step is one of the most potent cancer treatment strategies for improving the sensitivity of immunotherapy response. RESULTS: Here, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Haitao, Yu, Tianzhu, Li, Xin, Lei, Yangyang, Li, Jianke, Wang, Xiuhui, Peng, Peike, Ni, Dalong, Wang, Xiaolin, Luo, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686222/
https://www.ncbi.nlm.nih.gov/pubmed/34930269
http://dx.doi.org/10.1186/s12951-021-01197-5
_version_ 1784617972453605376
author Sun, Haitao
Yu, Tianzhu
Li, Xin
Lei, Yangyang
Li, Jianke
Wang, Xiuhui
Peng, Peike
Ni, Dalong
Wang, Xiaolin
Luo, Yu
author_facet Sun, Haitao
Yu, Tianzhu
Li, Xin
Lei, Yangyang
Li, Jianke
Wang, Xiuhui
Peng, Peike
Ni, Dalong
Wang, Xiaolin
Luo, Yu
author_sort Sun, Haitao
collection PubMed
description BACKGROUND: The construction of a nanoimmune controlled-release system that spatiotemporally recognizes tumor lesions and stimulates the immune system response step by step is one of the most potent cancer treatment strategies for improving the sensitivity of immunotherapy response. RESULTS: Here, a composite nanostimulator (CNS) was constructed for the release of second near-infrared (NIR-II) photothermal-mediated immune agents, thereby achieving spatiotemporally controllable photothermal-synergized immunotherapy. CNS nanoparticles comprise thermosensitive liposomes as an outer shell and are internally loaded with a NIR-II photothermal agent, copper sulfide (CuS), toll-like receptor-9 (TLR-9) agonist, cytosine-phospho-guanine oligodeoxynucleotides, and programmed death-ligand 1 (PD-L1) inhibitors (JQ1). Following NIR-II photoirradiation, CuS enabled the rapid elevation of localized temperature, achieving tumor ablation and induction of immunogenic cell death (ICD) as well as disruption of the lipid shell, enabling the precise release of two immune-therapeutical drugs in the tumor region. Combining ICD, TLR-9 stimulation, and inhibited expression of PD-L1 allows the subsequent enhancement of dendritic cell maturation and increases infiltration of cytotoxic T lymphocytes, facilitating regional antitumor immune responses. CONCLUSION: CNS nanoparticle-mediated photothermal-synergized immunotherapy efficiently suppressed the growth of primary and distant tumors in two mouse models and prevented pulmonary metastasis. This study thus provides a novel sight into photo-controllably safe and efficient immunotherapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01197-5.
format Online
Article
Text
id pubmed-8686222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86862222021-12-20 Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators Sun, Haitao Yu, Tianzhu Li, Xin Lei, Yangyang Li, Jianke Wang, Xiuhui Peng, Peike Ni, Dalong Wang, Xiaolin Luo, Yu J Nanobiotechnology Research BACKGROUND: The construction of a nanoimmune controlled-release system that spatiotemporally recognizes tumor lesions and stimulates the immune system response step by step is one of the most potent cancer treatment strategies for improving the sensitivity of immunotherapy response. RESULTS: Here, a composite nanostimulator (CNS) was constructed for the release of second near-infrared (NIR-II) photothermal-mediated immune agents, thereby achieving spatiotemporally controllable photothermal-synergized immunotherapy. CNS nanoparticles comprise thermosensitive liposomes as an outer shell and are internally loaded with a NIR-II photothermal agent, copper sulfide (CuS), toll-like receptor-9 (TLR-9) agonist, cytosine-phospho-guanine oligodeoxynucleotides, and programmed death-ligand 1 (PD-L1) inhibitors (JQ1). Following NIR-II photoirradiation, CuS enabled the rapid elevation of localized temperature, achieving tumor ablation and induction of immunogenic cell death (ICD) as well as disruption of the lipid shell, enabling the precise release of two immune-therapeutical drugs in the tumor region. Combining ICD, TLR-9 stimulation, and inhibited expression of PD-L1 allows the subsequent enhancement of dendritic cell maturation and increases infiltration of cytotoxic T lymphocytes, facilitating regional antitumor immune responses. CONCLUSION: CNS nanoparticle-mediated photothermal-synergized immunotherapy efficiently suppressed the growth of primary and distant tumors in two mouse models and prevented pulmonary metastasis. This study thus provides a novel sight into photo-controllably safe and efficient immunotherapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01197-5. BioMed Central 2021-12-20 /pmc/articles/PMC8686222/ /pubmed/34930269 http://dx.doi.org/10.1186/s12951-021-01197-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sun, Haitao
Yu, Tianzhu
Li, Xin
Lei, Yangyang
Li, Jianke
Wang, Xiuhui
Peng, Peike
Ni, Dalong
Wang, Xiaolin
Luo, Yu
Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
title Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
title_full Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
title_fullStr Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
title_full_unstemmed Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
title_short Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
title_sort second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686222/
https://www.ncbi.nlm.nih.gov/pubmed/34930269
http://dx.doi.org/10.1186/s12951-021-01197-5
work_keys_str_mv AT sunhaitao secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT yutianzhu secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT lixin secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT leiyangyang secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT lijianke secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT wangxiuhui secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT pengpeike secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT nidalong secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT wangxiaolin secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators
AT luoyu secondnearinfraredphotothermalamplifiedimmunotherapyusingphotoactivatablecompositenanostimulators